Multisensorial IMmersive Experiences (MIME) in Disorders of Consciousness
NCT ID: NCT05734183
Last Updated: 2025-03-20
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
20 participants
INTERVENTIONAL
2021-10-29
2024-10-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Simultaneous stimulation of multiple senses, such as hearing, sight and smell, provides the neural network with more stimuli that are more effective than a single stimulus. In fact, multisensory stimuli can more easily activate attention because cortical processing is predominantly multimodal. As for content, it would seem that those with autobiographical and emotionally salient character could engage multiple brain networks and have priority access to attention. Numerous trials show that stimulus-containing content led to increased behavioural activity, improving self-awareness in patients with DoC.
Considering that a communication system that can combine both visual and auditory channels proves to be more effective than a "single-sense" channel, multisensory stimulation is likely to provide simultaneous activation of different brain areas by enhancing plasticity processes. Furthermore, the intensity of stimulation could be one of the main variables with greater impact on the patient: in fact, higher intensity would correspond to a greater effect on the brain.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Olfactory Stimulation in Severe Brain Injury
NCT05747170
Neurophysiological Evaluation of Residual Cognitive Functions in Patients With Severe Alterations of Consciousness
NCT05802524
Cognitive-motor Dual Task Training in Patients With Multiple Sclerosis
NCT04619953
Neurophysiology of Surround Inhibition in the Human Motor Cortex
NCT03018262
Cognitive Embodiment Activation by tDCS
NCT03094520
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The purpose of the study is to evaluate (i) whether MIMEs can clinically modify the vigilance of DoC patients during administration; (ii) whether there is SNA activation during the administration of MIMEs; and (iii) whether patients treated daily with MIMEs have any benefits in terms of vigilance modification.
Twenty patients of both sexes with DoC will be recruited, evaluated and treated at the UOC of High Intensity Neurorehabilitation at the Fondazione Policlinico Universitario Gemelli IRCCS in Rome.
All study participants will undergo MIME treatment once a day for 5 days a week, for a total of 10 sessions. Patients will perform, in addition to MIME therapy, conventional rehabilitation as a daily routine. Patients will be divided into two groups: one part will perform MIME treatment concurrently with transcranial direct current stimulation (tDCS, G-Mt) and as many will undergo MIME treatment alone (G-M), as described below. In the case of epileptic subjects, these due to contraindications to tDCS may be subjected to MIME therapy only.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
MIME Group
Stimulation with MIME will be performed in a large ad hoc room in which video images will be projected on three walls. The patient will be positioned in the center of the room, 3 meters from the front wall, with the back of the bed tilted at a 45-degree angle, so as to obtain a truly immersive view covering the entire 220-degree field of view. Audio stimulation will be achieved through two speakers located at the sides of the room, with the low frequencies reinforced by a subwoofer. The average sound intensity recorded from the patient's position will be 81 db average (maximum 87, minimum 69).
Patients will undergo treatment with MIME once a day for five consecutive days, for a total of two weeks (10 sessions), in addition to conventional treatment.
MIME
Multisensorial IMmersive Experiences
MIME + tDCS Group
Simultaneously with MIME treatment, patients will undergo transcranial direct current stimulation (tDCS). Stimulation with tDCS will begin 5 minutes after the start of resting phase 1, and the electrodes will be placed as follows: the 5×4 anode (about 20 cm2) will be placed on the left dorsolateral prefrontal area; the reference electrode, 6x5 (about 30 cm2), will instead be placed on the upper arm, specifically at the level of the right deltoid muscle, contralateral to the active electrode. Current will be applied at an intensity of 2 mA, for 20 minutes a day for 2 weeks, five days a week, for a total of 10 sessions. The current density will be kept below the safe limits reported in the literature.
MIME + tDCS
Multisensorial IMmersive Experiences plus transcranial direct current stimulation
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
MIME
Multisensorial IMmersive Experiences
MIME + tDCS
Multisensorial IMmersive Experiences plus transcranial direct current stimulation
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Clinical stability Ability of caregiver/legal guardian to understand and sign informed consent
Exclusion Criteria
Psychiatric or other medical conditions Failure to sign informed consent The presence of a history of epilepsy and/or taking antiepileptic therapy is an exclusion criterion for assignment to the MIME+tDCS group.
18 Years
90 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
PADUA LUCA
Principal Investigator
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Luca Padua, MD, phD
Role: PRINCIPAL_INVESTIGATOR
Fondazione Policlinico Universitario A. Gemelli, IRCCS
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Fondazione Policlinico Universitario A. Gemelli IRCCS
Roma, RM, Italy
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
0038186/21
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.